跳至主要内容
临床试验/DRKS00013942
DRKS00013942已完成未知

Studies on the gastrointestinal hormone fibroblast growth factor 19 (FGF19) in overweight and obese patients with non-alcoholic fatty liver diseases (NAFLD)

niversität des Saarlandes0 个研究点目标入组 42 人开始时间: 2018年1月30日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • written consent,
  • Age: >18 years,
  • Controls: healthy and normal weight (BMI
  • 19.0-25.4 kg / m²),
  • overweight subjects (BMI 25.5-29.9 kg/m²) + NAFLD,
  • obese subjects (BMI = 30 kg m²) + NAFLD,
  • Liver diagnostics in overweight and
  • obese by ultrasound and/or liver biopsy

排除标准

  • missing declaration of consent,
  • NAFLD patients: increased alcohol consumption in medical history and the following acute and chronic liver diseases: cirrhosis, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) infections, hemochromatosis, Wilson's disease, a1-antitrypsin deficiency, and autoimmune hepatitis.

研究者

发起方
niversität des Saarlandes

相似试验

Studies on the gastrointestinal hormone fibroblast... | 临床试验